Stock ENVB ENVERIC BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.934 USD +4.08% Intraday chart for Enveric Biosciences, Inc. +5.90% -28.15%
Mar. 26 Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 19 Sector Update: Health Care Stocks Rise Late Afternoon MT

Evolution of the average Target Price on Enveric Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fb8a5453fa0be6d3304e66f5bb751f41.n3bblzAN59RK23nuWA6m9LrjISudXmIWSrJW-821P98.2DWL22ZU1eYBjQ3eO1HqjvaXdmauKQlJB9gXnoveDIWyDqH4AUGyiwmoQQ~7454f68b80111e17e3dbc5c86de8783e

Analyst Recommendations on Enveric Biosciences, Inc.

HC Wainwright Initiates Enveric Biosciences With Buy Rating, Price Target is $10 MT
Alliance Global Starts Enveric Biosciences at Buy With $1.25 Price Target MT
Aegis Capital Downgrades Enveric Biosciences to Hold from Buy, Adjusts Price Target to $0.20 from $7 MT
Maxim Group Adjusts Enveric Biosciences Price Target to $2 From $6, Maintains Buy Rating MT
ENVERIC BIOSCIENCES : Aegis Capital Starts Enveric Biosciences at Buy with $7 Price Target MT
ENVERIC BIOSCIENCES : Maxim Starts Enveric Biosciences at Buy With $6 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.934 USD
Average target price
9 USD
Spread / Average Target
+863.60%
High Price Target
10 USD
Spread / Highest target
+970.66%
Low Price Target
7 USD
Spread / Lowest Target
+649.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Enveric Biosciences, Inc.

HC Wainwright
Alliance Global Partners
Aegis Capital
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ENVB Stock
  4. Consensus Enveric Biosciences, Inc.